Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma
- 1 January 1992
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 80 (1) , 55-61
- https://doi.org/10.1111/j.1365-2141.1992.tb06400.x
Abstract
Summary. During the 3 years 1984–86, 314 cases of multiple myeloma were diagnosed in the Health Care Region of Western Sweden. 180 of these cases were included in a clinical trial; 71 were notified to the trial but excluded; 49 cases were not reported to the trial; 14 were diagnosed post mortem.The crude incidence rate of myeloma was 6.3 cases per 100000 inhabitants per year, corresponding to an age‐adjusted (world standard population) incidence rate of 2.9 cases per 100000 inhabitants per year.The excluded and the non‐reported patients had a significantly shorter survival than those included in the clinical trial (median survival 22, 13 and 33 months, respectively). This was partly due to differences in age and proportion of actively treeated patients between the groups, but the same tendency remained also after correction for these factors.Considering the included patients separately, the effect of tentative application of presumptive exclusion criteria corresponding to major prognostic factors was studied. Prolonged survival was seen when the upper age limit was lowered and when patients with renal failure or low performance status were excluded.The results illustrate the fact that for multiple myeloma the survival in a trial population is markedly influenced by active and passive exclusion of patient groups with unfavourable prognostic characteristics. When reporting results of clinical trials, discussion of the representativeness of the trial population for the total patient population is recommended in order to facilitate application of the trial results to medical practice and comparisons between trials.Keywords
This publication has 11 references indexed in Scilit:
- Classification and prognostic variables in myelomatosisScandinavian Journal of Haematology, 2009
- Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan‐prednisoneBritish Journal of Haematology, 1990
- Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland.BMJ, 1989
- Multiple Myeloma: Epidemiological Features in a Well-Defined Population in Burgundy, FranceInternational Journal of Epidemiology, 1989
- Trends in the incidence of multiple myeloma in Denmark 1943–1982: A study of 5500 patientsEuropean Journal of Haematology, 1989
- INCIDENCE AND OUTCOME OF MULTIPLE MYELOMA IN WESTERN AUSTRALIA, 1960 TO 1984Australian and New Zealand Journal of Medicine, 1988
- Prognostic factors and staging systems for multiple myeloma: Comparisons between the medical research council studies in the United Kingdom and the Southwest oncology group studies in the United StatesHematological Oncology, 1988
- Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experienceThe American Journal of Medicine, 1985
- Comparison of Trends in the Incidence of Multiple Myeloma in Malmö, Sweden, and Other Countries, 1950–1979New England Journal of Medicine, 1984